Drug Profile

Research programme: progesterone - Encore Therapeutics

Alternative Names: ETI-411; PE/Progesterone

Latest Information Update: 25 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Encore Therapeutics
Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules; Steroids
Mechanism of Action Progesterone receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
Available For Licensing Yes

Highest Development Phases

No development reported Brain injuries; Stroke

Most Recent Events

04 Nov 2017 No recent reports of development identified for research development in Brain injuries in USA (IV)
04 Nov 2017 No recent reports of development identified for research development in Stroke in USA (IV)
06 Apr 2011 Research is ongoing in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com